From Lab to Life: Transforming Medicine with Organ-on-Chip Technology

Developing new medicines is a lengthy and expensive process, often taking over a decade and billions of dollars to bring a single drug to market. Despite these investments, many drugs fail in late-stage clinical trials because current testing models struggle to predict how treatments will perform in the human body. Animal models, a cornerstone of preclinical testing, have significant limitations. Biological differences between humans and animals mean that results often don’t translate to clinical success. This not only wastes time and resources but also raises ethical concerns. To overcome these challenges, researchers are turning to innovative alternatives that better represent human biology.  

Organ-on-chip technology is one such breakthrough. These miniature systems recreate the environment of human tissues using living cells on a small, chip-like platform. Unlike static models, organ-on-chip devices can simulate dynamic processes such as blood flow and immune responses, providing a more accurate picture of how diseases progress or treatments work. My research focuses on advancing this technology to model critical barrier tissues, like the blood-brain barrier. These barriers regulate the movement of substances in and out of vital organs, making them essential for understanding how infections, toxins, or therapies affect the body. Traditional models are often static and lack fluid flow, which is key to mimicking real-life conditions.  

To address this, we’ve developed a reconfigurable platform that combines the simplicity of conventional methods with the dynamic capabilities of microfluidics. It starts with a familiar, user-friendly setup for growing cells and transitions seamlessly to a fluidic mode, simulating blood flow and other dynamic processes. This innovation allows researchers to explore complex interactions—like how immune cells respond to infection or how drugs cross barriers—without needing to overhaul their existing workflows. By making organ-on-chip systems more accessible and realistic, we aim to reduce reliance on animal models and accelerate the development of safer, more effective treatments. These advanced platforms are paving the way for a future where drug development is faster, more cost-effective, and more human.

​

​